Celularity Inc. Announces Receipt of Nasdaq Notification
27 nov. 2024 17h00 HE
|
Celularity Inc.
FLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company developing placental-derived allogeneic cell...
Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific
20 nov. 2024 08h30 HE
|
Celularity Inc.
Celularity is collaborating with its strategic partner, Genting Berhad, to bring Celularity placenta-derived allogeneic stem cell therapeutics to the Asia Pacific regionGenting Berhad announced...
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
18 nov. 2024 08h30 HE
|
Celularity Inc.
FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that the Nasdaq Listing...
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
07 nov. 2024 08h00 HE
|
Celularity Inc.
Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 MillionOctober Expected Net Sales of $8.3 Million to...
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
23 oct. 2024 08h30 HE
|
Celularity Inc.
FLORHAM PARK, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it has requested a hearing...
Celularity Provides Corporate Update
22 oct. 2024 08h30 HE
|
Celularity Inc.
FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from...
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal
18 oct. 2024 18h00 HE
|
Celularity Inc.
FLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing and commercializing placental-derived technologies,...
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.
16 oct. 2024 17h15 HE
|
Celularity Inc.
FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it had added to its commercial...
Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
05 sept. 2024 16h05 HE
|
Celularity Inc.
FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell...
Celularity Appoints Richard J. Berman to its Board of Directors
28 août 2024 16h45 HE
|
Celularity Inc.
FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative and cellular medicine company developing placental-derived allogeneic cell...